Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2PP3_Moderate
The NM_001406626.1(TSC1):c.-231T>A variant causes a 5 prime UTR premature start codon gain change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
TSC1 (HGNC:12362): (TSC complex subunit 1) This gene is a tumor suppressor gene that encodes the growth inhibitory protein hamartin. The encoded protein interacts with and stabilizes the GTPase activating protein tuberin. This hamartin-tuberin complex negatively regulates mammalian target of rapamycin complex 1 (mTORC1) signaling which is a major regulator of anabolic cell growth. This protein also functions as a co-chaperone for Hsp90 that inhibits its ATPase activity. This protein functions as a facilitator of Hsp90-mediated folding of kinase and non-kinase clients, including TSC2 and thereby preventing their ubiquitination and proteasomal degradation. Mutations in this gene have been associated with tuberous sclerosis and lymphangioleiomyomatosis. [provided by RefSeq, May 2022]
Gain of phosphorylation at F216 (P = 0.0311);.;Gain of phosphorylation at F216 (P = 0.0311);Gain of phosphorylation at F216 (P = 0.0311);Gain of phosphorylation at F216 (P = 0.0311);Gain of phosphorylation at F216 (P = 0.0311);Gain of phosphorylation at F216 (P = 0.0311);Gain of phosphorylation at F216 (P = 0.0311);Gain of phosphorylation at F216 (P = 0.0311);.;.;Gain of phosphorylation at F216 (P = 0.0311);Gain of phosphorylation at F216 (P = 0.0311);Gain of phosphorylation at F216 (P = 0.0311);Gain of phosphorylation at F216 (P = 0.0311);Gain of phosphorylation at F216 (P = 0.0311);.;Gain of phosphorylation at F216 (P = 0.0311);.;Gain of phosphorylation at F216 (P = 0.0311);